Eisai announces positive topline results from CAMELLIA-TIMI 61 large-scale trial
Eisai announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial. This 12,000 patient study of BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily was conducted at over 400 sites in eight countries in collaboration with the TIMI Study Group. July 17, 2018